about
Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a reviewOmalizumab in children.Omalizumab, an anti-immunoglobulin E antibody: state of the art.The role and choice criteria of antihistamines in allergy management - expert opinion.IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab.Omalizumab in an allergology clinic: real life experience and future developments.Immunotherapy in allergy and cellular tests: state of art.New strategies with anti-IgE in allergic diseasesCurrent recommendations and emerging options for the treatment of allergic rhinitis.An overview of the effects of anti-IgE therapies.The management of eosinophilic gastroenteritis.Off-Label Uses of Omalizumab.Treating IgE-mediated diseases via targeting IgE-expressing B cells using an anti-CεmX antibody.Comparable actions of omalizumab on mast cells and basophils.Dermatologic uses of omalizumabtitle.Advances in anti-IgE therapyOmalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study.Possible therapeutic role of IgE blockade in irritable bowel syndrome.Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines.Effect of anti-IgE in occupational asthma caused by exposure to low molecular weight agents.[Intolerance of specific immunotherapy with Hymenoptera venom: jumping the hurdle with omalizumab].Omalizumab an effective and safe alternative therapy in severe refractory atopic dermatitis: A case report.Omalizumab for Severe Asthma: Beyond Allergic Asthma
P2860
Q30801642-88C1DE1F-794B-4585-8DCD-28F51FB0D69DQ34604574-C88922AB-6EF1-49F6-B74B-0F04C83DC817Q35095218-AE17422B-CC62-4D41-A248-62D66895A0BEQ37531868-8B7DD8A1-3D29-42BB-8D51-2D776C66E3BCQ37554168-B8AFBBE2-D604-4DAC-9C64-26CE14F75D20Q37607069-D8518E68-BFA2-4695-A716-B2A7D7E5DC62Q37634329-B7CF50CA-EF0F-4A53-BAF1-E5594723F4AEQ38203380-4D9493C6-4B77-481B-9812-0A49352E0ADBQ38237389-DAC56191-CC14-45A3-9FAE-23A1DF6247BAQ38250070-7734C7BA-498F-4229-94E8-D427ECCB2566Q38252958-FB69EBA7-7DFB-4169-99F0-1900977B1F7EQ38509377-D5C03220-E960-43DA-BC0B-FB9FF8A06290Q38517653-5C025B4D-37A9-4E80-8AB3-686AA898E716Q38811111-80A541A8-1E99-4750-8472-1BDF8D57FF61Q38824255-07990AB6-0141-4856-8481-CAA788EAC35DQ38985255-967B4886-D051-4026-B170-6B67A560FB5CQ40812061-20BD634F-D529-4476-84B4-CD0F5609D0BEQ42293331-297FC240-107A-4E06-84C6-B1220FD548CAQ42365599-EA1B9117-4625-4510-9672-564E3183C1A5Q43981058-4EA2DD22-AB72-4688-9352-BBC66D481A21Q47218290-2B6876A7-224F-47EC-9052-6138F1AA8937Q52779210-B827E3B5-3C1B-4F83-A171-2E8F91EB27BAQ55438683-8913126D-4DA7-4928-9839-1BB1436F78C5Q57493273-07D47601-86CE-40FA-9149-4792C213B004
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Anti-IgE--emerging opportunities for Omalizumab.
@en
type
label
Anti-IgE--emerging opportunities for Omalizumab.
@en
prefLabel
Anti-IgE--emerging opportunities for Omalizumab.
@en
P2093
P2860
P1476
Anti-IgE--emerging opportunities for Omalizumab.
@en
P2093
Jaymin B Morjaria
K Suresh Babu
Riccardo Polosa
P2860
P304
P356
10.1517/14712598.2013.782391
P407
P577
2013-03-22T00:00:00Z